E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Metastatic RAS wild-type colorectal cancer which has previously responded to FOLFIRI chemotherapy and Cetuximab treatment but then progressed |
|
E.1.1.1 | Medical condition in easily understood language |
Advanced cancer of the colon or rectum which initially appeared to become smaller on treatment with FOLFIRI and Cetuximab treatment but now has either grown, reappeared or spread |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cancer [C04] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The principle objective of the iSCORE study is to evaluate how effective Nivolumab and Relatlimab is at controlling colorectal cancer 6 months after starting treatment in patients with RAS/RAF wild type metastatic colorectal cancers who initially had a response to first line Cetuximab and FOLFIRI treament but then progressed. This will be determined on a type of radiological scan, called a CT or MRI scan, which will be performed every 8 weeks for the first year and every 12 weeks for the second year. |
|
E.2.2 | Secondary objectives of the trial |
The iSCORE study will also determine how safe and tolerable (how much any side effects can be sensibly tolerated) Nivolumab and Relatlimab treatment is for patients with colon and rectal cancers and to assess further efficacy measures including obejective radiological response rate, progression free survival and overall survival.
We also have a number of exploratory objectives which aim to determine mechanisms of resistance to treatment and/or identify predictive or prognostic biomarkers to understand how combination immunotherapy can be further improved in this disease. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
• Male or female patients aged ≥18 years • Patients with histologically confirmed advanced/metastatic RAS/RAF wild type colon or rectal adenocarcinoma who had a prior radiological response to first line treatment with FOLFIRI and Cetuximab but have subsequently progressed/ become refractory to this treatment based on physician judgment • Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 • Estimated life expectancy of at least 3 months at the time of informed consent per Investigator assessment • Adequate organ functioning including haematological, renal, liver and cardiac function • Negative serum or urine pregnancy test at screening for women of childbearing potential and use of highly effective contraception for both male and female subjects throughout the study • Patient must consent and be eligible to undergo mandatory baseline and sequential biopsies • Presence of measurable disease as defined by RECIST v 1.1 criteria for response assessment
|
|
E.4 | Principal exclusion criteria |
• Systemic therapy within 4 weeks prior to the planned administration of the first study treatment dose • Major surgery within 4 weeks or radiation therapy within 14 days prior to study entry. Prior palliative radiotherapy to metastatic lesion(s) is permitted, provided it has been completed 48 hours prior to study entry and there is at least one measurable lesion that has not been irradiated.
• Previous exposure to immune checkpoint inhibitors or immune co-stimulatory drugs • Uncontrolled or significant cardiovascular disease including including patients with a history of myocarditis, regardless of aetiology • Known severe hypersensitivity reactions (Grade ≥ 3 NCI CTCAE v 5.0) to monoclonal antibodies or related compounds or any of their components • Current use of immunosuppressive medication, EXCEPT for the following: a. intranasal, inhaled, topical steroids, or local steroid injection (e.g., intra-articular injection); b. Systemic corticosteroids at physiologic doses ≤ 10 mg/day of prednisone or equivalent; c. Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication) • Known history of testing positive test for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome (AIDS) • Positive test for HBV surface antigen and / or confirmatory HCV RNA (if anti-HCV antibody tested positive) • Active, known or suspected autoimmune disease that might deteriorate when receiving an immuno-stimulatory agent. Subjects with type I diabetes mellitis, hypothyroidism only requiring hormone replacement, skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enroll. • Patients with a history of interstitial lung disease or radiological evidence of pulmonary fibrosis • Pregnancy or lactation • Vaccination within 4 weeks of the first dose of study drugs and while on trial is prohibited except for administration of inactivated vaccines
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary endpoint of the study is the proportion of patients who remain radiologically progression free at 6 months from treatment initiation i.e. disease control control rate (DCR) at 6 months. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
6 months from treatment initiation |
|
E.5.2 | Secondary end point(s) |
• The safety and tolerability profile of Nivolumab and Relatlimab in patients with metastatic CRC according to the NCI CTCAE version 5.0 toxicity aggregate
• Best Disease Control Rate (DCR), as defined above for the primary endpoint, at 12 months and 24 months from initiation of treatment
• Duration of disease control defined as the time between the initial response (radiological SD/CR/PR using RECIST 1.1 criteria) to therapy and subsequent disease progression/ relapse or relapsedeath. Progressive disease (PD) here will include clinical progression as well in the absence of radiological evidence. The disease control rate will be defined as either SD/CR/PR using RECIST 1.1 and iRECIST criteria). PD will include clinical progression as well
• Best Objective Response Rate (ORR) will be defined as either CR/PR (i.e. objective response using the RECIST 1.1 and iRECIST criteria). PD will include clinical progression as well. The timepoints of interest include 6 months, 12 months and 24 months from initiation of treatment
• Progression Free Survival (PFS) defined as time from registration to progression (radiological or clinical) or death.
• Overall Survival (OS) defined as time from registration to death.
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
6 months, 12 months and 24 months from treatment initiation |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 1 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The study end date is deemed to be the date of last data capture. Patient follow up will continue until death to evaluate the survival endpoint of the trial. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 3 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 3 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |